mybet Holding SE

  • WKN: A2LQ00
  • ISIN: DE000A2LQ009
  • Land: Deutschland

Nachricht vom 04.09.2018 | 15:01

mybet Holding SE: Closure of online sportsbook

mybet Holding SE / Key word(s): Miscellaneous
mybet Holding SE: Closure of online sportsbook

04-Sep-2018 / 15:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


mybet Holding SE: Closure of online sportsbook

The Management Board of mybet Holding SE ("Company") (ISIN DE000A2LQ009, new shares: ISIN DE000A2LQ7F4, convertible bond 2015/2020: DE000A1X3GJ8 and 2017/2020: DE000A2G8472), after conferring with the Supervisory Board, today decided to close the online sportsbook offered on mybet.com in order to protect the interests of customers and creditors.

The player funds are protected according to the Maltese "Gaming Player Protection Regulation". This means that the future withdrawal of funds by players is ensured.

The legal and regulatory requirements of this particular situation do mean, however, that withdrawals from player accounts will be subject to delays due to the necessary involvement of the Maltese Gaming Authority (MGA).

Information and Explanation of the Issuer to this News:

Reporting company:
mybet Holding SE, ISIN DE000A2LQ009, new shares: ISIN DE000A2LQ7F4 in the Prime Standard segment of the Frankfurt Securities Exchange

Reporting person:
Markus Peuler, member of the Management Board

Contact
mybet Holding SE
Karl-Liebknecht-Strasse 32
D-10178 Berlin
Investor & Public Relations
tel +49 30 22 90 83-161
fax +49 30 22 90 83-150
Email: ir@mybet.com


04-Sep-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021